Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 4/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.54 |
| ▸ | BACE1 | P56817 | 2/20 | 0.51 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.49 |
| ▸ | NPY1R | P25929 | 2/20 | 0.49 |
| ▸ | NPY4R | P50391 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.46 |
| ▸ | YWHAZ | P63104 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15985693 | 0.92 | TFPI (0.55) | TFPIRXFP1BACE1BACE2NPY5R | |
| SCHEMBL31157763 | 0.88 | NPY4R (0.53) | TFPIRXFP1BACE1BACE2NPY5R | |
| SCHEMBL31437196 | 0.86 | TFPI (0.48) | TFPIRXFP1NPY5RNPY1RNPY4R | |
| SCHEMBL31637662 | 0.85 | TFPI (0.60) | TFPIRXFP1 | |
| SCHEMBL31211755 | 0.85 | BACE1 (0.50) | TFPIRXFP1BACE1BACE2 | |
| SCHEMBL31211801 | 0.85 | BACE1 (0.50) | TFPIRXFP1BACE1BACE2 | |
| SCHEMBL31211765 | 0.85 | BACE1 (0.50) | TFPIRXFP1BACE1BACE2 | |
| SCHEMBL31211785 | 0.85 | BACE1 (0.50) | TFPIRXFP1BACE1BACE2 | |
| SCHEMBL31467753 | 0.83 | NPY4R (0.48) | TFPIBACE1BACE2NPY5RNPY1R | |
| SCHEMBL30974563 | 0.83 | TFPI (0.51) | TFPIRXFP1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748370-B2 | Peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation | STRONGBONE AB (SE) | 2014-06-10 | — | — | US | disclosed |
| US-20120108515-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | NEOBIOTICS AB (SE) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108515-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | BMP2, SOST, BMP1 | TFPI 896/4885RXFP1 43/4885BACE1 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.